PHAXIAM Therapeutics seeks buyer in receivership

PHAXIAM Therapeutics, a specialist in treatments for resistant bacterial infections, has launched a search for buyers as part of a receivership procedure. The call for tenders is open until April 11, 2025. The Lyon Commercial Court, which opened this procedure on March 6, 2025, will rule on its extension on April 30, 2025.

The company, listed on Euronext Paris, will not publish its financial results before the deadline of April 30, 2025. It expects to be able to finance its operations until June 2025, after which it could be liquidated if no solution is found. PHAXIAM's shares will resume trading on Euronext Paris on March 17, 2025.